Organophosphate poisoning Injury, Occupational Diseases, Poisoning Organophosphate poisoning
Conditions
Interventions
We plan to conduct a double-blind randomised controlled trial of the effectiveness of early magnesium treatment in preventing death. Patients will be randomised to magnesium sulphate or a placebo in
Sponsors
South Asian Clinical Toxicology Research Collaboration (SACTRC) (Sri Lanka)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with symptomatic acute OP
Exclusion criteria
Exclusion criteria: 1. Patients who do not consent 2. Pregnant women 3. Patients less than 16 years of age 4. Patients who are hypotensive (blood pressure less than 90/50 mmHg) on presentation and not responding to intravenous (iv) fluids and atropine 5. Patients who have ingested other substances in addition to OP 6. Patients with other major medical conditions (e.g. cardiovascular disease renal or hepatic failure)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the number of patients dying in those receiving magnesium versus those receiving placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will include need for ventilation, blood pressure, level of consciousness and duration of atropine therapy. Adverse events reported by doctors will be rated by them as to the likelihood of them being due to magnesium infusion (certain, probable, possible, unlikely). | — |
Countries
Sri Lanka
Outcome results
None listed